irinotecan has been researched along with singlet oxygen in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ge, X; Jiang, H; Li, F; Shen, J; Wei, S; Zhou, J; Zhou, L | 1 |
| Hurst, R; Rahman, KMM; Thapa, P; Woo, S; You, Y | 1 |
| Beharry, AA; Kailass, K; Sadovski, O; Zipfel, WR | 1 |
3 other study(ies) available for irinotecan and singlet oxygen
| Article | Year |
|---|---|
Combination of chemotherapy and photodynamic therapy using graphene oxide as drug delivery system.
Topics: Antineoplastic Agents; Biological Transport; Camptothecin; Cell Line, Tumor; Drug Carriers; Graphite; Humans; Irinotecan; Oxides; Perylene; Phenol; Photochemotherapy; Photosensitizing Agents; Quinones; Singlet Oxygen | 2014 |
Singlet Oxygen Activatable Prodrugs of Paclitaxel, SN-38, MMC and CA4: Nonmitochondria-Targeted Prodrugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Irinotecan; Mitomycin; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Prodrugs; Singlet Oxygen | 2022 |
Two-Photon Photodynamic Therapy Targeting Cancers with Low Carboxylesterase 2 Activity Guided by Ratiometric Fluorescence.
Topics: Fluorescence; Humans; Irinotecan; Neoplasms; Photochemotherapy; Photosensitizing Agents; Prodrugs; Singlet Oxygen | 2022 |